The coming 12 months will prove significant for Clinuvel as we anticipate the flow of communication and news to increase. As part of our preparation for upcoming developments and to ensure we are well placed to face the challenges unique to reaching our clinical, regulatory and business objectives, we’ll be making some changes to our online communication channels.
In the coming weeks we will be updating elements of our online presences and this may result in some downtime for our various websites and inevitable bugs and consequent troubleshooting exercises.
If you have any input or ideas as to how we could improve the corporate or photoprotection websites, the Clinuvel blog or Twitter feed please feel free to leave a comment on this post. We’ll consider all suggestions and are looking forward to your input.
We apologise in advance for any inconvenience experienced during this time and hope you benefit from the updates and developments we are implementing.
Last month saw the conclusion of the FDA’s public hearing on the internet promotion of drugs. This was the first time the agency has directly addressed and engaged key stakeholders in regards to online policy and guidelines since 1996, 
As you know, the Clinuvel AGM is fast approaching (18th November) in Melbourne, Australia. While we are inherently an Australian company, we recognise that there are a substantial number of stakeholders worldwide who are interested in our news and developments.
Today, and in the coming weeks I shall review the increasingly complex phenomenon in the pharmaceutical industry called off-label drug use. 
While we firmly believe at Clinuvel that communication and online dialogue is a most valuable tool to inform shareholders, prospective patients and physicians, the boundaries of drug promotion are being drawn as we speak.
Manufacturing drugs for human use is a complicated process frequently involving compounds and materials that, if used incorrectly, can be hazardous to people’s health. Highly regulated nations (such as the US, EU, Australia and Canada) have long realised the necessity that they develop strict guidelines governing these processes to protect patients and ensure product safety, quality and efficacy. Poor quality drugs, manufacturing processes or conditions can have extreme and dire consequences for patients. In countries that enforce Good Manufacturing Practice (GMP) the penalties for non-adherence reflect its importance and can include forcing worldwide product recalls, seizure of property, large fines, even imprisonment.
A most interesting movement that’s gathering steam within pharmaceutical development is that of Green Pharma.
The millisecond transfer of data packs has changed medicine for good. When it comes to gaining online information about our health the pros outweigh the cons. We are seeing in modern medicine that patients are well prepared when seeking health consultation. Sites such as 
